Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr 17;24(8):7400.
doi: 10.3390/ijms24087400.

Scandium-44: Diagnostic Feasibility in Tumor-Related Angiogenesis

György Trencsényi  1 , Zita Képes  1
Affiliations
Review

Scandium-44: Diagnostic Feasibility in Tumor-Related Angiogenesis

György Trencsényi et al. Int J Mol Sci. .

Abstract

Angiogenesis-related cell-surface molecules, including integrins, aminopeptidase N, vascular endothelial growth factor, and gastrin-releasing peptide receptor (GRPR), play a crucial role in tumour formation. Radiolabelled imaging probes targeting angiogenic biomarkers serve as valuable vectors in tumour identification. Nowadays, there is a growing interest in novel radionuclides other than gallium-68 (68Ga) or copper-64 (64Cu) to establish selective radiotracers for the imaging of tumour-associated neo-angiogenesis. Given its ideal decay characteristics (Eβ+average: 632 KeV) and a half-life (T1/2 = 3.97 h) that is well matched to the pharmacokinetic profile of small molecules targeting angiogenesis, scandium-44 (44Sc) has gained meaningful attention as a promising radiometal for positron emission tomography (PET) imaging. More recently, intensive research has been centered around the investigation of 44Sc-labelled angiogenesis-directed radiopharmaceuticals. Previous studies dealt with the evaluation of 44Sc-appended avb3 integrin-affine Arg-Gly-Asp (RGD) tripeptides, GRPR-selective aminobenzoyl-bombesin analogue (AMBA), and hypoxia-associated nitroimidazole derivatives in the identification of various cancers using experimental tumour models. Given the tumour-related hypoxia- and angiogenesis-targeting capability of these PET probes, 44Sc seems to be a strong competitor of the currently used positron emitters in radiotracer development. In this review, we summarize the preliminary preclinical achievements with 44Sc-labelled angiogenesis-specific molecular probes.

Keywords: Arg-Gly-Asp (RGD); aminobenzoyl–bombesin analogue (AMBA); aminopeptidase N (APN/CD13); angiogenesis; carcinogenesis; gastrin-releasing peptide receptor (GRPR); integrin; nitroimidazole; positron emission tomography (PET); scandium-44 (44Sc).

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Sc44- and Sc47-labelled peptide-based radiopharmaceuticals in the molecular imaging and therapy of cancer-related angiogenesis.
See this image and copyright information in PMC

References

    1. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 2002;29:15–18. doi: 10.1053/sonc.2002.37263. - DOI - PubMed
    1. Jiménez B. Mechanistic insights on the inhibition of tumor angiogenesis. J. Mol. Med. 2001;78:663–672. doi: 10.1007/s001090000178. - DOI - PubMed
    1. Hanahan D., Folkman J. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis. Cell. 1996;86:353–364. doi: 10.1016/S0092-8674(00)80108-7. - DOI - PubMed
    1. Folkman J. Tumor angiogenesis. In: Holland J.F., Frei E. III, Bast R.C. Jr., editors. Cancer Medicine. 5th ed. B.C. Decker; Hamilton, ON, Canada: 2000. pp. 132–152.
    1. Folkman J. Angiogenesis. In: Braunwald E., Fauci A.S., Kasper D.L., Hauser S.L., Longo D.L., Jameson J.L., et al., editors. Harrison’s Principles of Internal Medicine. 15th ed. McGraw-Hill; New York, NY, USA: 2001. pp. 517–530.

LinkOut - more resources